Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial
Sign Up to like & getrecommendations! Published in 2021 at "BMC Cancer"
DOI: 10.1186/s12885-021-08612-y
Abstract: Background Here we evaluated the feasibility, efficacy, tolerability, and treatment-mediated immune modulation of neoadjuvant everolimus plus letrozole versus chemotherapy in treating postmenopausal patients with ER-positive, HER2-negative breast cancer. Methods Postmenopausal women with ER-positive, HER2-negative breast… read more here.
Keywords: breast; positive her2; plus letrozole; neoadjuvant everolimus ... See more keywords